WithdrawnNot Applicable

Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia

Stopped: As of 12/18/2017 notification of early closure of the trial due to lack of recruitment.

Spain0Started 2013-09-16

Plain-language summary

* Androgenetic alopecia (AGA) or common baldness is the most common cause of hair loss in both men and women and is caused by the action of androgens in genetically predisposed individuals. * This clinical trial was designed to evaluate the efficacy and safety of using a preparation of autologous plasma rich in growth factors (PRGF-Endoret) in the treatment of androgenetic alopecia.

Who can participate

Age range

18 Years – 65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Androgenetic alopecia according to the following scales: * Men: Hamilton/Norwood Scale: grades II-VI * Women: Ludwig Scale grades I-II. * Possibility of follow-up during the study Exclusion Criteria: * No androgenetic alopecia * Telogen and anagen effluvium * Active inflammation or infection in the intervention area * Presence of active systemic infections. * Background of cancerous or precancerous lesions. * Background of connective or rheumatic diseases. * Suffering from any serious blood disorders. * To have undergone treatments for alopecia in the previous 6 months. * Previous hair implants * Intake of drugs that affect hair loss. * Be undergoing immunosuppressive therapy and/or anticoagulants. * Known intolerance to mesotherapy. * Taking contraceptives containing cyproterone acetate. * Pregnancy * In general, any limitations that would prevent the proper application of both treatments and the right monitoring of the efficacy variables.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change from baseline in Hair density at three months (number of hairs per cm2)

Timeframe: 3 months post-treatment

Trial details

NCT IDNCT01885676

SponsorBiotechnology Institute IMASD

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-09

View on ClinicalTrials.gov More Androgenetic Alopecia trials